Pharmaceutica Analytica Acta

Status of biosimilars in India

International Conference on Bio-Pharmaceuticals, Biosimilars & Pharma Industry

February 28 - March 01, 2019 Osaka, Japan

Anjana Male

Nirmala College of Pharmacy, India

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

Biosimilars drugs are organic products that are having similar identical in pharmacodynamic and pharmacotherapeutic action to that of the branded drugs but can be available at a cheaper cost. Current scenario of biosimilars in Indian industry has its first massive break in 1984. Biosimilars market place in India presently include eight biosimilars, the main aim of introducing biosimilars drugs in Indian market is to increase patient access to biological therapy and to reduce health care cost. In India biosimilar has engrossed large investments in the areas of research, clinical trials and manufacturing. The expiry of patent protection for many biological drugs has given the scope for development of biosimilar drugs with low cost and high therapeutic action. Biosimilar drugs are facing many challenges for getting into market as well as approval process is more complicated too. India being one of the most preferred manufacturing destinations of biosimilar drugs.

Biography :

E-mail: anjana.nrml@gmail.com